Shefali Agarwal
Vorstandsvorsitzender bei VALERIO THERAPEUTICS
Vermögen: 40 596 $ am 30.04.2024
Aktive Positionen von Shefali Agarwal
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FATE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 15.07.2019 | - |
| Independent Dir/Board Member | 15.07.2019 | - | |
| GRITSTONE BIO, INC. | Direktor/Vorstandsmitglied | 01.06.2021 | - |
| Independent Dir/Board Member | 01.06.2021 | - | |
| VALERIO THERAPEUTICS | Vorsitzender | 29.07.2021 | - |
| Vorstandsvorsitzender | 06.04.2022 | - | |
| Präsident | 06.04.2022 | - | |
| Direktor/Vorstandsmitglied | 01.06.2021 | 29.07.2021 | |
| Independent Dir/Board Member | 01.06.2021 | 29.07.2021 |
Karriereverlauf von Shefali Agarwal
Ehemalige bekannte Positionen von Shefali Agarwal
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EPIZYME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2018 | 06.04.2022 |
| SQZ BIOTECHNOLOGIES COMPANY | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2017 | 01.05.2018 |
Ausbildung von Shefali Agarwal
| Karnataka University | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
| Merrick School of Business | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
| Indien | 2 |
| Frankreich | 2 |
Operativ
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Shefali Agarwal
- Erfahrung
